- 1 **Title:** Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer 2
- 3 Authors: Connor B. Grady¹, MPH; Wei-Ting Hwang¹, PhD; Joshua E. Reuss², MD; Wade
- 4 Iams³, MD, MSCI; Amanda Cass³, PharmD; Geoffrey Liu⁴, MD; Devalben Patel⁴, MD; Stephen
- 5 V. Liu², MD; Gabriela Liliana Bravo Montenegro², MD; Tejas Patil⁵, MD; Jorge J. Nieva⁶, MD;
- 6 Amanda Herrmann⁶, MD; Kristen A. Marrone⁷, MD; Vincent K. Lam⁷, MD; William
- 7 Schwartzman⁸, MD; Jonathan Dowell⁸, MD; Liza C Villaruz⁹, MD; Kelsey Leigh Miller¹⁰, MD;
- 8 Jared Weiss¹⁰, MD; Fangdi Sun¹¹, MD; Vamsidhar Velcheti, MD¹²; D. Ross Camidge⁵, MD,
- 9 PhD; Charu Aggarwal¹³, MD, MPH; Lova Sun¹³, MD, MSCE; Melina E. Marmarelis¹³, MD,
- 10 MSCE
- 11

12 Affiliations:

- ¹Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, 423
- 14 Guardian Drive, Philadelphia, PA 19104
- ² Department of Medicine Georgetown University, 3800 Reservoir Road NW, Washington, DC
- 16 20007
- ³ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical
- 18 Center, 2220 Pierce Ave, 780 PRB, Nashville, TN 37232
- ⁴ Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON M5G 2C4, Canada
- ⁵ University of Colorado Cancer Center, 1665 Aurora Court, MS F704, Aurora, CO 80045
- 21 ⁶ University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue
- 22 NOR 3400, Los Angeles, CA 90033
- ⁷ Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD 21224
- ⁸ Harold C Simmons Comprehensive Cancer Center, UT Southwestern, 6202 Harry Hines, Blvd,
- 25 9th Floor, Dallas Texas, 75235
- ⁹ UPMC Hillman Cancer Center, 5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232
- ¹⁰ Lineberger Comprehensive Cancer Center, 170 Manning Drive, Room 3115, Chapel Hill, NC
- 28 27599
- 29 ¹¹ UCSF School of Medicine, University of California San Francisco, 533 Parnassus Ave, San
- 30 Francisco, CA 94143
- 31 ¹² NYU Grossman School of Medicine, 550 1st Ave, New York, NY 10016

- ¹³ Department of Medicine, Division of Hematology and Oncology, Perelman School of
- 33 Medicine, University of Pennsylvania, 3400 Civic Center Blvd, 10th Floor, South Tower,
- 34 Philadelphia, PA 19104.
- 35

36 Corresponding author:

- 37 Melina E. Marmarelis, MD, MSCE
- 38 Department of Medicine, Division of Hematology & Oncology
- 39 Perelman School of Medicine
- 40 3400 Civic Center Blvd, 10th Floor, South Tower
- 41 Philadelphia, PA 19104
- 42 Email: Melina.Marmarelis@pennmedicine.upenn.edu
- 43
- 44 **Conflict of Interest Statements:**
- 45 CBG, WH, AC, GL, DP, GLBM, AH, WS, JD, KLM, VV, DRC: No conflicts of interest
- 46 associated with current work.
- 47 JER: Advisory Board / Consultant:Genentech/Roche, Sanofi/Genzyme, Personalis, Guardant,
- 48 Astrazeneca, BMS, Arcus, Abbvie, Daiichi Sankyo. Research Funding (to institution):
- 49 Genentech/Roche, Verastem, Nuvalent, Mesothelioma Applied Research Foundation,
- 50 LUNGevity Foundation. Honoraria/Speaking Fees: Astrazeneca, Merck
- 51 WI: Consultant for OncLive, Clinical Care Options, Chardan, Cello Health, Curio Science.
- 52 Advisory Board/DSMC for Genentech, Mirati, Outcomes Insights, Jazz Pharmaceuticals, GI
- 53 Therapeutics, Takeda, AstraZeneca, Sanofi, Janssen, Amgen, Bristol Myers Squibb, NovoCure.
- 54 SVL: Advisory Board / Consultant for Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim,
- 55 Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche,
- 56 Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis,
- 57 Regeneron, Sanofi, Takeda, Turning Point Therapeutics. Research grant (to institution)
- 58 from Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT,
- 59 Turning Point Therapeutics. Data Safety Monitoring Board for Candel Therapeutics.
- 60 TP: Advisory Role (advisory boards or consultations) in last 3 years: Astrazeneca, Biocept,
- 61 Boehringer Ingelheim, Bristol-Myers Squibb, Bicara, Caris, Guardant Health, Guidepoint, EMD
- 62 Soreno, Janssen, Jazz Pharamceuticals, Mirati Therapeutics, Natera, Pfizer, Sanofi, Regeneron,

- 63 Roche/Genentech, Takeda. Advisory Committees: Elevation Oncology (DSMB). Research
- 64 Funding: EMD Soreno, Janssen, Gilead
- 5 JN: Stock/Ownership interests in Epic Sciences, Cansera, Quantagene, Indee P/L. Consulting for
- 66 AstraZeneca, Naveris, Aadi biosciences, Bioatla, Mindmed, ANP Technologies. Research
- 67 funding to institution from Merck, Genentech. Patent pending on movement and unexpected
- 68 healthcare encounters.
- 69 KAM has received consulting/advisory fees from AstraZeneca, Amgen, Janssen, Mirati
- 70 Therapeutics, Daiichi Sankyo/Lilly and Puma Biotechnology, as well as Honoraria from
- 71 AstraZeneca. KAM receives research funding to Johns Hopkins University from Bristol-Myers
- 72 Squibb and Mirati Therapeutics.
- 73 V.K.L. reports serving in a consultant/advisory role for Seattle Genetics, Bristol-Myers Squibb,
- 74 AstraZeneca, Guardant Health, Takeda, and Anheart Therapeutics, and has received research
- 75 funding from BMS, Merck, Seattle Genetics, Astra Zeneca
- 76 LCV reports researching funding from Janssen, BMS, Merck, Regeneron, GSK, AstraZeneca,
- 77 BioAtla, Black Daimon Therapeutics, Jazz, Genentech, Beigene. Consulting fees from Takeda,
- 78 Janssen, Intervenn Biosciences, Sanofi, Daiichi Sankyo, Jazz, BMS, Gilead.
- 79 CA reports receiving institutional research funding from AstraZeneca, Genentech, Incyte,
- 80 Macrogenics, Medimmune, and Merck Sharp & Dohme, and receiving consultation fees from
- 81 Genentech, Lilly, Celgene Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/
- 82 Astra Zeneca, Regeneron/ Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, Boehringer
- 83 Ingelheim.
- 84 LS reports research funding from Blueprint (Inst), Seagen (Inst), IO Biotech (Inst), Erasca (Inst).
- 85 Consulting with Sanofi Genzyme, Regeneron, GenMab, Seagen, and Bayer.
- 86 MEM reports researching funding from Eli Lilly (Inst), AstraZeneca (Inst), Merck (Inst),
- 87 Genentech (Inst) consulting role with Astra Zeneca, Novocure, Boehringer Ingelheim, Janssen,
- 88 Takeda, Blueprint Pharmaceuticals, Bayer, Bristol Myers Squibb, Ikena; Honorarium from
- 89 Thermo Fisher; stock in Merck, Johnson & Johnson.
- 90
- 91 Funding: This work is supported in part by grants from Takeda, AstraZeneca and LUNGevity.
- 92 Keywords: Non-small cell lung cancer, EGFR, ALK, ROS1, real-world data
- **93 Word Count**: 1196

94 Abstract

95 Introduction: Determining lines of therapy (LOT) using real-world data is crucial to inform 96 clinical decisions and support clinical research. Existing rules for determining LOT in patients 97 with metastatic non-small cell lung cancer (mNSCLC) do not incorporate the growing number of 98 targeted therapies used in treatment today. Therefore, we propose rules for determining LOT from 99 real-world data of patients with mNSCLC treated with targeted therapies.

- 100 Methods: LOT rules were developed through expert consensus using a real-world cohort of 550
- 101 patients with ALK+ or ROS1+ mNSCLC in the multi-institutional, electronic medical record-based
- 102 Academic Thoracic Oncology Medical Investigators Consortium's (ATOMIC) Driver Mutation
- 103 Registry. Rules were subsequently modified based on a review of appropriate LOT determination.
- 104 These resulting rules were then applied to an independent cohort of patients with EGFR+
- 105 mNSCLC to illustrate their use.
- 106 **Results:** Six rules for determining LOTs were developed. Among 1133 patients with EGFR
- 107 mutations and mNSCLC, a total of 3168 regimens were recorded with a median of 2 regimens per
- 108 patient (IQR, 1-4; range, 1-13). After applying our rules, there were 2834 total LOTs with a median
- 109 of 2 LOTs per patient (IQR, 1-3; range, 1-11). Rules 1-3 kept 11% of regimen changes from
- 110 advancing the LOT. When compared to previously published rules, LOT assignments differed
- 111 5.7% of the time, mostly in LOTs with targeted therapy.
- 112 Conclusion: These rules provide an updated framework to evaluate current treatment patterns, 113 accounting for the increased use of targeted therapies in patients with mNSCLC and promote 114 standardization of methods for determining LOT from real-world data.
- 115

116 Key Points

- Use of targeted therapy to treat patients with mNSCLC is growing
- Determining lines of therapy from real-world data is crucial for clinical research
- Our rules aim to advance the line of therapy to reflect changes in clinical status
- Using these rules can lead to better method harmonization in mNSCLC research

121 Introduction

122 When using real-world data to answer clinical questions in oncology, accurate 123 determination of lines of therapy (LOT) using treatment records is crucial to conducting 124 meaningful analyses. In the absence of detailed information on progression and toxicity, 125 investigators rely on treatment records alone to infer changes in clinical disease status and 126 determine LOTs. This non-uniform methodology may cause significant variation in how LOTs are 127 defined depending on malignancy type, data source, and treatment patterns. Standardized rules and 128 algorithms for determining LOTs are needed to improve the reproducibility and comparability of 129 real-world data analyses.

There is tremendous opportunity for impactful analysis of real-world data from patients with metastatic non-small cell lung cancer (mNSCLC), but standardized LOT determination has been difficult. Systemic therapies for mNSCLC now include immunotherapy, chemotherapy, and targeted therapies, which can be used alone or in combination. Because of this, treatment patterns and sequencing are complex and heterogeneous¹. This is particularly true for the subset of patients with mNSCLC and rare molecular characteristics and patients with co-morbidities where complex treatment patterns and outcomes are only captured outside of clinical trials.

Previously, others have proposed algorithms for determining LOTs for patients with solid tumors, lung cancer, and mNSCLC.² However, these algorithms do not specifically incorporate common treatment patterns for patients with targetable alterations, such as *EGFR*, *ALK*, and *ROS1* alterations. In this report, we aim to propose new rules for determining LOT from real-world data of patients with mNSCLC, focusing on treatment patterns among patients receiving targeted therapies.

143

144 Methods

We defined a regimen as any systemic anticancer agent (i.e., chemotherapy, immunotherapy, or targeted therapy) or combination of systemic agents administered at the same time. First, we developed rules for determining LOT ("LOT rules") by expert consensus and review of existing literature. Next, these rules were applied to treatment records from 550 patients with mNSCLC and sensitizing *ALK* or *ROS1* fusions in the ATOMIC Driver Mutation Registry. ATOMIC is a multi-institutional collaborative of twelve academic centers across North America. Trained data abstractors used a standardized digital form to record patients' regimen agent(s) and

start/end dates. Finally, thoracic oncologist members of ATOMIC reviewed the LOT determination and revised the rules to reflect practice patterns most indicative of changes to clinical disease status. These modified rules were then applied to a separate ATOMIC cohort of 1,133 patients with mNSCLC and *EGFR* sensitizing mutations. Rules were also developed to identify LOTs that are most likely applicable to early-stage disease ("ESD rules") since data sources of patients with mNSCLC may inadvertently include treatments for this disease stage.

In this report, we demonstrate the use of LOT and ESD rules on treatment records from the ATOMIC *EGFR* cohort. We compared our LOT determination with those of an existing algorithm for mNSCLC proposed by Hess et al using the SAS macro %mnsclc_lot². Analyses were performed in R version 4.2.1³ and SAS software version 9.4. This study was approved by the University of Pennsylvania Institutional Review Board (IRB #829009).

163

164 **Results**

We propose six rules for determining LOT in real-world data of patients with mNSCLC (**Table 1, Figure 1**). Among 1,133 patients in ATOMIC with *EGFR* alterations and mNSCLC, a total of 3168 regimens were recorded with a median of 2 regimens per patient (IQR, 1-4; range, 1-13). After applying our rules, there were 2834 total LOTs with a median of 2 LOTs per patient (IQR, 1-3; range, 1-11). Rules 1-3 prevented 334 regimen changes from advancing the LOT (**Table** 1). Thirty-seven patients switched regimens within 28 days of the start of the first LOT and had a line 0.5 recorded.

Comparatively, after applying an algorithm proposed by Hess et al. to the same treatment records, there were 2771 total LOTs with a median of 2 per patient (IQR 1-3; range 1-9). Among our method's 3999 agent-LOT assignments (e.g., osimertinib as 1L, carboplatin as 2L, etc.), ours differ from the Hess method in 5.7% of assignments (Table 2).

Additionally, we developed two rules to remove systemic therapy agents likely used in the treatment of early-stage disease (ESD) from the LOT determination. (1) If a LOT was durvalumab monotherapy administered prior to November 11, 2022 (i.e., prior to Food and Drug Administration approval for durvalumab in stage IV NSCLC)⁴ or (2) if the LOT was chemotherapy with a cumulative cycle duration of 30-140 days and no subsequent LOT for at least four months of follow-up, the LOT should be considered as a treatment for early-stage disease and excluded from the patient's LOT enumeration for mNSCLC. Among patients in ATOMIC with *EGFR*

alterations and mNSCLC, the first LOT for 81 patients met the criteria for early-stage disease
treatment (ESD Rule 1 met for two patients and ESD Rule 2 met for 79). These LOTs were
removed, and the remaining LOTs were renumbered as LOTs for mNSCLC.

186

187 **Discussion**

We propose six simple rules to determine whether a change in treatment for mNSCLC should or should not advance the LOT in real-world data. Our LOT assignments led to different classifications from previous work in 5.7% of cases, primarily in characterizing targeted therapycontaining regimens. Since LOT assignment can affect outcome measures such as real-world progression-free survival or time to treatment discontinuation, even small differences may lead to different conclusions in an observational study. Therefore, it is critical that the LOT determination accurately reflects clinical practice.

195 There are several ways that our proposed rules better characterize LOTs in mNSCLC 196 populations treated with targeted therapy compared to previously reported methods 197 (Supplemental table 1).^{2,4–7} First, we distinguish between biologics and therapies targeting 198 oncogenic drivers in mNSCLC. This distinction is important because biologics, such as 199 angiogenesis inhibitors, may have little anti-tumor activity alone and are often added or removed 200 from treatment regimens without a clear change in disease status, while targeted therapies have 201 tremendous anti-tumor activity and are used in the setting of a change in disease status. Second, 202 there are instances where targeted therapies are added to or replace a previous regimen because of 203 a newly identified targetable mutation and not because of a change in disease status. The rules 204 proposed allow for this approach by allowing for 1 cycle of chemotherapy to be given while 205 waiting for molecular testing results prior to switching to a targeted therapy without advancing the 206 LOT. Third, we allow for a treatment pause and re-initiation within 60 days to be considered the 207 same LOT, which may be more appropriate for targeted therapies typically taken daily by mouth 208 that are paused and restarted for toxicity.⁵⁻⁷

Retrospective determination of whether a treatment was given in the setting of metastatic disease versus early-stage disease is critical to determining real-world clinical endpoints. In this historical dataset, we used rules based on the approved therapies at the time of the dataset, but even while completing the analysis for this study the indications for several systemic therapies expanded to include early-stage disease, making the agent itself an unreliable indicator of early-stage

214 treatment. Given this complexity, extracting the date of metastatic diagnosis at the time of data 215 abstraction will become even more important to evaluate the practice patterns contemporary to the 216 time of the dataset. 217 We believe wider use of this framework for LOT determination could lead to better method 218 harmonization of observational studies in mNSCLC and allow for comparison and aggregation 219 across datasets in the future. 220 221 Acknowledgements 222 This work is supported in part by grants from Takeda, AstraZeneca and LUNGevity. 223 224 References 225 1. Hess LM, Cui ZL, Li XI, Molife C, Oton AB. Treatment sequencing for the care of 226 patients with advanced or metastatic non-small cell lung cancer in the United States. Curr Med 227 Res Opin. 2021;37(3):469-476. doi:10.1080/03007995.2020.1866516 228 2. Hess LM, Li X, Wu Y, Goodloe RJ, Cui ZL. Defining treatment regimens and lines of 229 therapy using real-world data in oncology. Future Oncol Lond Engl. 2021;17(15):1865-1877. 230 doi:10.2217/fon-2020-1041 231 3. R Core Team. R: A language and environment for statistical computing. Published online 232 2022. https://www.R-project.org/. 233 4. Food and Drug Administration. IMFINZI® (durvalumab) injection, for intravenous use. 234 Published online November 1, 2022. Accessed March 28, 2023. 235 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf 236 5. Abernethy AP, Arunachalam A, Burke T, et al. Real-world first-line treatment and 237 overall survival in non-small cell lung cancer without known EGFR mutations or ALK 238 rearrangements in US community oncology setting. PLoS ONE. 2017;12(6):e0178420. 239 doi:10.1371/journal.pone.0178420 240 6. Johnston S, Wilson K, Varker H, et al. Real-world Direct Health Care Costs for 241 Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing 242 Regimens in First-line or First-line Through Second-line Therapy. Clin Colorectal Cancer. 243 2017;16(4):386-396.e1. doi:10.1016/j.clcc.2017.03.014

- 244 7. Meng W, Mosesso KM, Lane KA, et al. An Automated Line-of-Therapy Algorithm for
- 245 Adults With Metastatic Non-Small Cell Lung Cancer: Validation Study Using Blinded Manual
- 246 Chart Review. JMIR Med Inform. 2021;9(10):e29017. doi:10.2196/29017

247

248 **Tables and figures**

240	Table 1. Drong	and miles for line	of the many de	tomination from	real-world treatmen	tragimona
249	Table I. Flope	ulles for the	of therapy de		real-world treatmen	it regimens.

		Example	Example LOT	Frequency
Rule	Line of therapy stays the same:	regimen change	determination	rule applied ^a
1	If any agent is introduced within 28 days	Day 0-21:	0.5L ^b (Day 0-21):	109
	of the start of the first regimen of the	Carboplatin,	Carboplatin +	
	current LOT.	Pemetrexed	Pemetrexed	
		Day 14-400:	1L (Day 14-400):	
	TA	Brigatinib	Brigatinib	-
2	If an angiogenesis inhibitor (e.g.,	Day 0-80:	1L (Day 0-200):	1
	bevacizumab, ramucirumab) is introduced	Osimertinib	Osimertinib +	
	within 90 days from the start of the first	D 00 000	Bevacizumab	
	regimen of the current LOT.	Day 80-200:		
		Osimertinib,		
2		Bevacizumab	1L (D 0.110)	22.4
3	If the gap between the end of the prior and	Day 0-30:	1L (Day 0-110):	224
	the start of the current regimens is ≤ 60	Entrectinib	Entrectinib	
	days and the current regimen uses	D 00.110		
	a. the same agent(s),	Day 80-110:		
	b. an exchange of interchangeable agents	Entrectinib		
	(e.g., Carboplatin/Cisplatin,			
	Paclitaxel/Nab-paclitaxel), or			
	c. a reduced regimen			
		Example	Example LOT	Frequency
Rule	Line of therapy advances:	regimen change	determination	rule applied ^a
4	If an angiogenesis inhibitor (e.g.,	Day 1-120:	1L (Day 1-120):	22
	bevacizumab, ramucirumab) is introduced	Osimertinib	Osimertinib	
	>90 days after the start of the first			
	regimen of the current LOT.	Day 121-160:	2L (Day 121-160)	
		Osimertinib +	Osimertinib +	
		ramucirumab	ramucirumab	
5	If the one between the and of the universe t	Day 1 200:	11.(Day 1.200)	24
5	If the gap between the end of the prior and the start of the current regimens is >60	Day 1-200: Alectinib	1L (Day 1-200):	34
	e	Aleculio	Alectinib	
	days and the current regimen uses	D_{23} 300 400.	2L (Day 300-400):	
	a. the same agent(s),	Day 300- 400: Alectinib	Alectinib	
	b. an exchange of interchangeable agents	AICUIIIO	AICUIIIU	
	(e.g., Carboplatin/Cisplatin,			
	Paclitaxel/Nab-paclitaxel),			
	c. a reduced regimen			

6	If a new non-interchangeable agent is	Day 1-42:	1L (Day 1-42):	1645
	added to a regimen or is introduced after	Carboplatin +	Carboplatin +	
	the discontinuation of all prior agents >28	pemetrexed	pemetrexed	
	days after the start of the first regimen of			
	the current LOT.	Day 43-700:	2L (Day 43-700)	
		Lorlatinib	Lorlatinib	


^a Number of times rule is applied in the ATOMIC *EGFR* cohort

^b When a regimen is discontinued followed by the start of a new regimen all within 28 days of

the start of the first line of therapy, the first regimen is assigned a line number of 0.5 while still

253 being considered part of first-line therapy. LOT, line of therapy

Figure 1: Algorithm for line of therapy determination



255

- 256 **Table 2:** Example line of therapy determination differences between the proposed rules and
- 257 other (Hess et al.) rules

Patient	Duration of regimen (days)	Regimen agent(s)	Proposed LOT	Hess et al. LOT
Patient A	0-150	Erlotinib	1	1
	151-242	Osimertinib	2	2
	243-438	Bevacizumab, Carboplatin, Pemetrexed	3	3
	439-674	Pemetrexed	3	3
	675-702	Bevacizumab, Pemetrexed	4	3
	703-849	Pemetrexed	4	3
	881-ongoing	Bevacizumab, Erlotinib	5	3
Patient B	0-630	Bevacizumab, Erlotinib	1	1
	632-1036	Osimertinib	2	2
	1038-1091	Osimertinib, Crizotinib	3	2
Patient C	0	Bevacizumab, Carboplatin, Pemetrexed	1	1
	30-800	Erlotinib	2	2
	802-904	Bevacizumab, Carboplatin, Pemetrexed	3	3
	905-1010	Bevacizumab, Pemetrexed	3	3
	1205-1849	Osimertinib	4	4
	1851-2035	Osimertinib, Gefitinib	5	4

258 Highlighted cells indicate differences in how lines of therapy are determined between the

259 proposed rules and other (Hess et al.) rules. LOT, line of therapy.

260 **Supplemental table 1**: Differences between proposed rules and Hess et al. rules

	Line of therapy advances		
Scenario	Proposed rules	Hess et al. rules	
Targeted or immunotherapy is added to a regimen 28+ days after the start of the first regimen in the current LOT.	Yes	No	
Targeted or immunotherapy is started with discontinuation of all agents in prior regimen.	Yes* *Except if started <28 days from start of LOT	Yes	
An interchangeable agent is exchanged 60+ days after the end of the prior regimen.	Yes	No	
Introduction of an anti-angiogenic agent <90 days from the start of any LOT, with or without discontinuation of the prior regimen.	No	Yes* *Except if pemetrexed is part of prior regimen and given with anti- angiogenic agent in the first LOT	
A regimen is reduced but with a gap in treatment of 60+ days. (e.g., Day 0-60: Carboplatin + Alectinib, Day 140- ongoing: Alectinib)	Yes	Not addressed in rules	

261 LOT, line of therapy